Figure 3.

Confocal immunofluorescence studies demonstrate that enzalutamide decreases AR (red) and c-Myc (green) in GBM cells cultured in vitro (U87MG and MGPP3). (A) U87MG cells were treated with DMSO (negative control) or various concentrations of enzalutamide (20 µM or 40 µM). (B) MGPP3 cells were treated with DMSO or various concentrations of enzalutamide (20 µM or 40 µM). (C) LnCap (prostate cancer cell line) served as a positive control. (D) Quantification of the immunofluorescence signals of AR and c-Myc in U87MG and MGPP3 cell lines after enzalutamide treatment (20 µM or 40 µM) for 24 h. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.